By Fineline Cube 
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5 million shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100 million.
TruMed Health: A Proven Investor in Biopharma
TruMed Health Innovation Fund is a specialist investment vehicle focused on biopharmaceutical ventures. The fund has a strong track record in Hong Kong, having acted as a cornerstone investor in IPOs for Kelun‑Biotech, Bliss Biopharmaceutical, and Ascentage Pharma. Its reputation makes it a bellwether in the region’s healthcare investment landscape.
Strategic Use of Proceeds
InxMed plans to deploy the capital primarily to optimise its financial structure and accelerate its research‑and‑development pipeline. The infusion is intended to reinforce the company’s balance sheet and fund the next generation of bispecific antibody programs.
Accelerating a Bispecific Antibody Portfolio
The raised capital will underpin pre‑clinical and clinical studies for several cutting‑edge bispecific antibody candidates, including QX027N, QX031N, and QX035N. These projects are positioned to bring new therapeutic options to global markets, strengthening InxMed’s market competitiveness and long‑term growth prospects.
Looking Ahead
With the private placement now closed, InxMed is set to leverage the strengthened financial base to push its R&D agenda forward, aiming to deliver novel bispecific therapies that address unmet medical needs and expand its footprint in the global biopharmaceutical arena.-Fineline Info & Tech